MedTrace Logo

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study

NCT01077908 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2018-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential clinical benefit of prophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.

Conditions

  • Cytomegalovirus Infection

Interventions

BIOLOGICAL

Adoptive Cellular Therapy

CMV-specific T-cells, single infusion at 27 days post-HSCT

DRUG

Best available antiviral drug therapy

1. Intravenous ganciclovir 5mg/kg twice daily 2. Oral valganciclovir 900mg twice daily 3. Intravenous foscarnet 90 mg/kg twice daily

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • EMAS Pharma

    collaborator INDUSTRY

  • Commitum AB

    collaborator INDUSTRY

  • BioAnaLab

    collaborator UNKNOWN

  • Cell Medica Ltd

    lead INDUSTRY

Principal Investigators

  • Karl S Peggs · University College London Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01077908 on ClinicalTrials.gov